tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Muraki Y et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. 2011 Oct-Dec Ann. Transplant. pmid:22210422
Boratyńska M et al. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. 2006 Ann. Transplant. pmid:17494290
Foroncewicz B et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. 2013 Ann. Transplant. pmid:23896824
Grochowiecki T et al. A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. 2006 Ann. Transplant. pmid:17494291
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Fox BD et al. Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. 2017 Ann. Transplant. pmid:29133776
Rehman S et al. Effect of different tacrolimus levels on early outcomes after kidney transplantation. 2014 Ann. Transplant. pmid:24509826
Legris T et al. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. 2013 Ann. Transplant. pmid:24231646
Bäckman L and Persson CA An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. 2014 Ann. Transplant. pmid:24637379
Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. 2001 Ann. Transplant. pmid:11803619
Steinebrunner N et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. 2014 Ann. Transplant. pmid:24457606
Gijsen VM et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. 2012 Apr-Jun Ann. Transplant. pmid:22743729
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Baron PW et al. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. 2017 Ann. Transplant. pmid:28533501
Furmańczyk A et al. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009155
Gerlach UA et al. Aspergillus spondylodiscitis after multivisceral transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009156
Malinowski M et al. Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. 2010 Jul-Sep Ann. Transplant. pmid:20877268
Roan JN et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. 2013 Ann. Transplant. pmid:23792500
Tanaka T et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. 2013 Ann. Transplant. pmid:23792533
Ueda K et al. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. 2014 Ann. Transplant. pmid:24535029
El-Agroudy AE et al. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. 2008 Ann. Transplant. pmid:19034223
Augusto JF et al. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. 2013 Ann. Transplant. pmid:23872516
Zegarska J et al. Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. 2015 Ann. Transplant. pmid:26313036
Figurski MJ et al. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. 2012 Jan-Mar Ann. Transplant. pmid:22466911
Acott P and Babel N BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? 2012 Jan-Mar Ann. Transplant. pmid:22466913
Bułanowski M et al. Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. 2012 Jul-Sep Ann. Transplant. pmid:23018257
Baran DA and Galin ID "One size fits all": immunosuppression in cardiac transplantation. 2003 Ann. Transplant. pmid:12848376
Eguchi S et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. 2007 Ann. Transplant. pmid:18344932
Zahn A et al. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. 2013 Ann. Transplant. pmid:24088725
Garaix F et al. Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. 2018 Ann. Transplant. pmid:30093607
WÅ‚odarczyk Z et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. 2002 Ann. Transplant. pmid:12465429
Matia I et al. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. 2014 Ann. Transplant. pmid:24815872
Park S et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. 2018 Ann. Transplant. pmid:29891834
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Urbanowicz T et al. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. 2014 Ann. Transplant. pmid:24949728
Fuchs U et al. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. 2014 Ann. Transplant. pmid:24953848
Hošková L et al. Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. 2016 Ann. Transplant. pmid:27226081
Bösmüller C et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. 2012 Ann. Transplant. pmid:23274323
Olczak-Kowalczyk D et al. The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. 2012 Ann. Transplant. pmid:23274327
Zakliczyński M et al. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. 2005 Ann. Transplant. pmid:16218032
Ruangkanchanasetr P et al. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. 2016 Ann. Transplant. pmid:27980321
Kitazawa F et al. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Ann. Transplant. pmid:28947731
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Hirano Y et al. Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. 2017 Ann. Transplant. pmid:28798289
Illsinger S et al. Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. 2011 Apr-Jun Ann. Transplant. pmid:21716189
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Mijal J et al. Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. 2002 Ann. Transplant. pmid:12854345
Albano L et al. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. 2016 Ann. Transplant. pmid:27122116
Wyzgał J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. 2007 Ann. Transplant. pmid:18173063